The State Council's new office held a press conference, and the deputy director of the National Health Insurance Administration responded to questions related to volume procurement, and will carry out the centralized procurement of new batches of drugs in due course...
01
The ninth batch of national procurement or start
Provincial and local alliances continue to collect
On May 18, the State Council Information Office held a series of themed press conferences on "The Beginning of the Authoritative Department", introducing the relevant situation of "implementing the 20 major decisions and deployments of the Party and focusing on promoting the high-quality development of medical insurance", in which Shi Zihai, Li Tao, and Huang Huabo, deputy directors of the National Health Insurance Administration, mentioned information about procurement with volume in the next work plan for 2023 when answering reporters' questions.
Next, the procurement with volume will still be institutionalized and normalized, and the centralized procurement of new batches of drugs will be carried out in a timely manner.
Starting from the two dimensions of national procurement and local centralized procurement, the national procurement will mainly carry out the fourth batch of high-value medical consumables, mainly for ophthalmic intraocular lenses and orthopedic sports medicine consumables, and will also carry out a new batch of drug centralized procurement in due course; Local centralized procurement mainly focuses on the procurement of chemical drugs, proprietary Chinese medicines, interferons, neurosurgical consumables, in vitro diagnostic reagents, etc. other than the centralized procurement of national organizations.
This is following the National Health Insurance Administration's issuance of the Notice on Doing a Good Job in Centralized Procurement and Price Management of Pharmaceuticals in 2023 in March this year, pointing out that the new batch of centralized procurement of drugs has been promoted in a timely manner, and the official has once again spoken out about the possibility of launching a new national procurement in the future.
From May 9th to 12th, Shi Zihai, deputy director of the National Health Insurance Administration, went to Henan and Guizhou to investigate the price and centralized procurement of drugs on the Internet, and mentioned that he would adhere to the high quality of the price management and centralized procurement of drugs on the Internet. It is necessary to unswervingly expand the coverage of centralized procurement of pharmaceutical consumables and pay close attention to the quality of centralized procurement implementation.
At the national level, it has been mentioned many times that the centralized procurement of drug consumables has expanded the scope, and it has become a trend to unswervingly promote the centralized procurement of drug consumables.
At present, volume procurement still plays an important role. Hu Jinglin, director of the National Health Insurance Administration, mentioned that in the past five years, the National Health Insurance Administration has purified the ecology of the pharmaceutical industry, institutionalized and normalized centralized procurement with volume, continued to squeeze the inflated price of drug consumables, and compressed the space for "gold sales".
The eighth batch of national procurement has been released by more than 15 provinces one after another, and the declaration and confirmation of the eighth batch of national procurement and second reserve enterprises has been carried out one after another. Today, Tianjin Pharmaceutical Procurement Center issued the Notice on Convening the Eighth Batch of National Organization Drug Centralized Procurement Results Implementation Enterprise Training Meeting, and the eighth batch of national procurement implementation in Tianjin has been put on the agenda.
In July, the eighth batch of national procurement will basically land nationwide, and it is expected that the ninth batch of national procurement will begin soon.
02
Nearly 60 large varieties
It basically meets the conditions for national procurement
For a long time, varieties with full competition and large market scale have been the key objects of national centralized procurement.
According to the WeChat public account of "Yilian Recruitment", up to now, there are more than 60 varieties with 5 or more evaluated enterprises. The varieties with more than 10 competitive patterns include sitagliptin phosphate tablets (16+1), ambroxol hydrochloride oral solution (13+0), alogliptin benzoate tablets (11+1), desloratadine oral solution (11+0), levalbutamol hydrochloride nebulized inhalation solution (10+0), cefotiam hydrochloride for injection (10+0), etc.
According to data from Minai.com, 22 of the 40 varieties included in the eighth batch of national procurement exceeded 1 billion yuan in terminal sales in China's public medical institutions in 2021, with the highest sales exceeding 8 billion yuan; Among the 59 varieties included in the seventh batch of national procurement, 22 had sales of more than 1 billion yuan in 2021, and the highest sales exceeded 6 billion yuan.
At present, the total sales scale of terminals in China's public medical institutions has exceeded 27 billion yuan in 2022 for varieties that are not included in centralized procurement and meet more than 5 competitive conditions.
From the perspective of therapeutic areas, the collection of varieties covers a wide range, including nervous system drugs, digestive system and metabolic drugs, systemic anti-infective drugs and respiratory system drugs.
Competition is still intensifying, according to the competition of previous batches of national procurement, basically competitors have 3 or more evaluated varieties. The seventh batch has 4 minimum competitors, and the eighth batch of competitors has ≥ 5.
The number of varieties that have been rated 5 or more is still increasing. For example, on May 10, in the latest drug approval certificate issued by the State Food and Drug Administration, the sodium acetate Ringer injection of Hunan Kelun Pharmaceutical and Shijiazhuang Four Medicines was evaluated on the same day, and the number of evaluated companies has reached 5.
Leading pharmaceutical companies are still the main force of national procurement competition, such as Yangzijiang, China Biopharmaceutical, Chengdu Beite, Kelun and so on. According to data from Minai.com, at present, Yangtze River, Chengdu Beite, China Biopharmaceutical, Kelun Pharmaceutical and CSPC Pharmaceutical Group have 14, 10, 10, 7 and 7 evaluated varieties that meet the shortlisted conditions of 5 or more.
Once the ninth batch of national procurement is launched, the competition should not be underestimated.
03
The pace of local collective procurement has accelerated
The latest news of the collection and procurement of proprietary Chinese medicine alliance was announced
According to the tone set by the above meeting, the next local centralized procurement will revolve around chemical drugs, proprietary Chinese medicines, interferons, etc. other than national procurement.
Recently, the pace of local centralized procurement has gradually accelerated, and the second batch of centralized procurement of proprietary Chinese medicines led by Hubei has announced the latest news.
Just now, the National Joint Procurement Office of Proprietary Chinese Medicines issued the "National Proprietary Chinese Medicine Procurement Alliance Centralized Procurement Document", which was composed of Hubei, Beijing, Tianjin, Hebei, Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Shanghai, Jiangsu, Zhejiang, Anhui, Jiangxi, Shandong, Henan, Guangdong, Guangxi Zhuang Autonomous Region, Hainan, Chongqing, Sichuan, Guizhou, Yunnan, Tibet Autonomous Region, Shaanxi, Gansu, Qinghai, Ningxia Hui Autonomous Region, Xinjiang Uygur Autonomous Region, The Xinjiang Production and Construction Corps and other alliance regions appointed representatives to form a national joint procurement office for proprietary Chinese medicines to carry out centralized procurement of proprietary Chinese medicines and related drugs.
The procurement is divided into 16 groups, namely: compound cantharid, compound thrombosis, coronary heart ning, hua toadin, elderberry seventh, le pulse, vascular rehabilitation, cerebral an, garcinia and bone, xiangdan, xinkeshu, awakening brain calm, crow bile oil, ginkgo damole, ginkgo biloba leaf extract, and zhenyuan (see the annex at the end of the article for the specific list).
On May 15, the Liaoning Provincial Medical Institutions Drug and Medical Consumables Procurement Alliance issued a notice that the Liaoning Province, Shanxi Province, Inner Mongolia Autonomous Region, Jilin Province, Heilongjiang Province, Hainan Province, Guizhou Province, Qinghai Province, Tibet Autonomous Region, Ningxia Hui Autonomous Region, Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps formed an inter-provincial procurement alliance to establish the Office of the Leading Group for the Centralized Procurement of Hernia Mesh and Hard Brain (Spinal Membrane) Patch. Carry out centralized procurement of medical consumables on behalf of public medical institutions (including military medical institutions) in the alliance region and designated social medical institutions that voluntarily participate.
In early May, a "letter on inviting to participate in the centralized procurement of the drug alliance" circulated in the industry, Henan intends to lead the formation of an inter-provincial alliance to carry out centralized procurement of 31 varieties such as inosine injection and cyclic adenosine injection, according to the document plan, the provinces with the intention to participate have written to Henan Medical Insurance Bureau before May 6, and it is expected that the follow-up official documents will be released in the near future.
At the same time, some news of the renewal of the collective procurement contract is being announced one after another. The large varieties of interferon in the market of more than one billion also released centralized procurement information, and subsequently, various places may successively join the interprovincial alliance led by Jiangxi.
Attached: Chemical drugs with 5 or more enterprises that meet the declaration conditions and are not included in the centralized procurement
Note: Some drugs may not be included in the collective procurement due to patent period, product attributes, etc., and all information is subject to the official!
Image/data source: Minai.com
List of centralized procurement varieties of the National Proprietary Chinese Medicine Procurement Alliance
Inter-provincial alliance patch category centralized procurement documents
Henan intends to take the lead in forming an inter-provincial alliance to collect 31 varieties (for reference only, the actual situation is subject to the official announcement)
END